ICON Acquires Veeda Labs

ICON has acquired Veeda Laboratories Ltd., a provider of biomarker laboratory services to pharmaceutical and biotechnology companies. The acquisition adds to ICON’s bioanalytical and immunoassay capabilities provided at its lab in Manchester, UK, and through Prevalere Life Sciences in the U.S.

“Biomarkers of disease are assuming an ever increasing role in the discovery and development of drugs,” commented Thomas Frey, president, ICON Development Solutions. “In Veeda Laboratories, we have acquired a company that has a very strong reputation for biomarker development and has well-established relationships with top-tier pharmaceutical and biotechnology companies. Veeda’s team of scientists will also greatly enhance ICON’s existing team of biomarker experts.”

“We are excited to be joining ICON,” commented John Allinson, head of Veeda Laboratories, Oxford. “This deal will enable us to enhance and expand our biomarker, pharmacokinetic and immunogenicity services and to offer our clients a broader suite of drug development services. We look forward to working closely with ICON’s global network of laboratories to develop innovative biomarker solutions that improve clients’ drug development and therapeutic decision making.”